JP2024542831A5 - - Google Patents
Info
- Publication number
- JP2024542831A5 JP2024542831A5 JP2024533880A JP2024533880A JP2024542831A5 JP 2024542831 A5 JP2024542831 A5 JP 2024542831A5 JP 2024533880 A JP2024533880 A JP 2024533880A JP 2024533880 A JP2024533880 A JP 2024533880A JP 2024542831 A5 JP2024542831 A5 JP 2024542831A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163286345P | 2021-12-06 | 2021-12-06 | |
| US63/286,345 | 2021-12-06 | ||
| US202263317573P | 2022-03-08 | 2022-03-08 | |
| US63/317,573 | 2022-03-08 | ||
| US202263370056P | 2022-08-01 | 2022-08-01 | |
| US63/370,056 | 2022-08-01 | ||
| PCT/US2022/080928 WO2023107894A1 (en) | 2021-12-06 | 2022-12-05 | Combination therapy comprising a pkc inhibitor and a c-met inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024542831A JP2024542831A (ja) | 2024-11-15 |
| JPWO2023107894A5 JPWO2023107894A5 (https=) | 2025-12-15 |
| JP2024542831A5 true JP2024542831A5 (https=) | 2025-12-15 |
Family
ID=86731264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024533880A Pending JP2024542831A (ja) | 2021-12-06 | 2022-12-05 | Ｐｋｃ阻害剤及びｃ－ｍｅｔ阻害剤を含む併用療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240335440A1 (https=) |
| EP (1) | EP4444303A4 (https=) |
| JP (1) | JP2024542831A (https=) |
| AU (1) | AU2022407330A1 (https=) |
| CA (1) | CA3239676A1 (https=) |
| IL (1) | IL313361A (https=) |
| MX (1) | MX2024006948A (https=) |
| WO (1) | WO2023107894A1 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014174478A1 (en) * | 2013-04-26 | 2014-10-30 | Novartis Ag | Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor |
| CA2955676A1 (en) * | 2014-08-25 | 2016-03-03 | Pfizer Inc. | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
| US11413284B2 (en) * | 2017-09-12 | 2022-08-16 | Novartis Ag | Protein kinase C inhibitors for treatment of uveal melanoma |
| AU2020386903A1 (en) * | 2019-11-18 | 2022-06-09 | Ideaya Biosciences, Inc. | Dosing regimens for a protein kinase C inhibitor |
| JP2023541011A (ja) * | 2020-09-08 | 2023-09-27 | イデアヤ、バイオサイエンシズ、インコーポレイテッド | 医薬組み合わせおよび腫瘍治療 |
-
2022
- 2022-12-05 JP JP2024533880A patent/JP2024542831A/ja active Pending
- 2022-12-05 MX MX2024006948A patent/MX2024006948A/es unknown
- 2022-12-05 WO PCT/US2022/080928 patent/WO2023107894A1/en not_active Ceased
- 2022-12-05 US US18/715,927 patent/US20240335440A1/en active Pending
- 2022-12-05 EP EP22905269.1A patent/EP4444303A4/en active Pending
- 2022-12-05 IL IL313361A patent/IL313361A/en unknown
- 2022-12-05 CA CA3239676A patent/CA3239676A1/en active Pending
- 2022-12-05 AU AU2022407330A patent/AU2022407330A1/en active Pending